New hope for rare tumor type: first human trial of PEP08 begins
NCT ID NCT06973863
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 23 times
Summary
This early-phase study tests a new drug called PEP08 in people with advanced solid tumors that have lost a gene called MTAP. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. About 40 adults will receive PEP08 alone or with another cancer drug.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
China Medical University Hospital
RECRUITINGTaichung, Taiwan
-
National Taiwan University Hospital
RECRUITINGTaipei, Taiwan
-
Taipei Veterans General Hospital
RECRUITINGTaipei, Taiwan
-
Westmead Hospital
RECRUITINGWentworthville, New South Wales, 2145, Australia
Conditions
Explore the condition pages connected to this study.